Recommendation of the President – Tavneos (avacopan)
On 2 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 137/2024 on the appraisal Tavneos (avacopan) under the drug program “Treatment of patients with active granulomatosis with vasculitis (GPA) or microscopic vasculitis (MPA) (ICD-10: M31.3, M31.8)”